Open Protocols

Stamford Hospital/Medical Oncology Hematology Research

Primary

/

Disease Stage

/

Protocol

/

Title

Breast / Adjuvant / NCIC MA.32
Dr. Angevine
Mary Miller, LPN / A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Breast / Adjuvant / NSABP B-49
Dr. Weinstein
Mary Miller, LPN / A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Digestive/GI
Colon / Adjuvant / NSABP P-5
Dr. Del Prete
Ed Hatton, RN / Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
Digestive/GI
Colorectal / Genentech ML25710
Dr. Del Prete
Ed Hatton, RN / A Randomized Phase II Study of Bevacizumab/mFOLFOX6 vs. Bevacizumab/FOLFIRI with Biomarker Stratification in Patients with Previously Untreated Metastatic Colorectal Cancer (MAVERICC)
Digestive/GI
Colorectal / Gilead GS-US-205-0203
Dr. Del Prete
Ed Hatton, RN / A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma that has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen
Digestive/GI
Colorectal / Metastatic / NCCTG N0949
Dr. Del Prete
Ed Hatton, RN / Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer
Digestive/GI
Pancreatic / Metastatic / Gilead GS-US-324-0101
Dr. Del Prete
Ed Hatton, RN / A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Digestive/GI
Pancreatic / Recurrent or Metastatic / INCYTE INCB 18424-262
Dr. Del Prete
Ed Hatton, RN / A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination with CApecitabine for Subjects with recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP trial)
Digestive/GI
Pancreatic / Adjuvant Stage I or II
Resected R0 or R1 / NewLink NLG-0405
Dr. Del Prete
Ed Hatton, RN / A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute®-Pancreas (algenpantucel-L) Immunotherapy is Subjects with Surgically Resected Pancreatic Cancer
Genitourinary/GU
Bladder / Metastatic / CALGB 90601
Dr. Cohen
Ed Hatton, RN / A Randomized Doubled-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma
Genitourinary/GU
Prostate / Dendron P10-3
Dr. Cohen
Mary Miller, LPN / A Registry of Sipuleucel-T® Therapy in Men with Advanced Prostate Cancer (PROCEED)
Genitourinary/GU
Prostate / Sanofi-Aventis EFC11784
Dr. Cohen
Ed Hatton, RN / Randomized, Open Label, Multi-Center Study comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m2 in combination with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer not Pretreated with Chemotherapy (Study Name: FIRSTANA)
Genitournary/GU
Prostate / Sanofi-Aventis EFC11785
Dr. Cohen
Ed Hatton, RN / Randomized, Open-Label Multi-Center Study comparing Cabazitaxel at 20 mg/m2 and at 25 mg/m2 Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated with a Docetaxel-Containing Regimen (Study Name: PROSELICA)
Genitourinary/GU
Renal / Metastatic / CALGB 90802
Dr. Del Prete
Sue Murdock, RN / Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab For Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors
GYN - Ovarian, Primary Peritoneal, or Fallopian Tube Cancers / Amgen 20101129
Dr. Del Prete
Sue Murdock, RN / A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of AMG 386 with Paclitaxel and Carboplatin as First-line Treatment of Subjects with Figo Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers (TRINOVA-3)
GYN
Ovarian / II-IV or recurrent stage I / GOG-0241Dr.Del Prete
Sue Murdock, RN / A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865, IND #113912) Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)
GYN
Ovarian / Merrimack MM-121-04-02-08Dr. Del Prete
Sue Murdock, RN / A Phase II Randomized Open Label Study of MM-121 in Combination with Paclitaxel Versus Paclitaxel Alone in Patients with Platinum Resistant/Refractory Advanced Ovarian Cancers
GYN
Uterus / I-IV / GOG-0261Dr.Del Prete
Sue Murdock, RN / A Randomized Phase III Trial of Paclitaxel Plus Carboplatin versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus
Hematologic Malignancy / Celgene Connect CLLDr. Bar
Sue Murdock, RN / Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Lymphoma / Diffuse Large B-Cell / Cell Therapeutics PIX306Dr. Angevine
Sue Murdock, RN / A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-Cell Non-Hodgkin’s Lymphoma Who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant
Multiple Myeloma / MMRF-11-001Dr. Bar
Sue Murdock, RN / A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles (CoMMpass)
Pulmonary/Lung
NSCLC / Adjuvant
IB-IIIA /

ECOG 1505

Dr. Del Prete
Ed Hatton, RN / A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB (≥ 4cm) – IIA Non-Small Cell Lung Cancer (NSCLC)
Pulmonary/Lung
NSCLC /

Genentech GO27912

Dr. Del Prete
Ed Hatton, RN / A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab with and without GDC-0941 in Patients with Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer
Pulmonary/Lung /

Millennium C14007

Dr. Del Prete

Mary Miller, LPN

/ A Phase I Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Non-hematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Melanoma / Stage III/IV /

E1609

Dr. Del Prete
Ed Hatton, RN / A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon α-2b for Resected High-Risk Melanoma

\\server\data\WORDDOCS\FORMS\DATAMGR\Open Protocols.doc 11JAN12, 2FEB12, 20Feb12; 8MAR12, 22MAY12, 24MAY12, 4JUN12, 7JUN12

Copy to: C: Builes, C. Di Bona, D. Derdelinghen, L. Manfredo, , K. Radziewicz, M. Ronk, D. Sardanovic, E. Johnson Page1 of 3